| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4001924 | American Journal of Ophthalmology | 2016 | 11 Pages |
Abstract
The RPE atrophy developed in 5.4% of eyes with neovascular AMD during the 26.7Â months of ranibizumab treatment. When compared with white individuals, RPE atrophy developed less frequently in Japanese patients, but the progression rate was similar. The subtype of AMD thus affects the development of RPE atrophy.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Yoshimasa Kuroda, Kenji Yamashiro, Akitaka Tsujikawa, Sotaro Ooto, Hiroshi Tamura, Akio Oishi, Hideo Nakanishi, Masahiro Miyake, Munemitsu Yoshikawa, Nagahisa Yoshimura,